Alacris startet eine zweite Crowdfundingrunde mit Seedmatch. Begleiten Sie uns auf die nächste Stufe der Markterweiterung in Europa und in den USA.
Unterstützen Sie mit Ihrem Investment, dass mehr und mehr Patienten eine der genauesten und individuellsten Krebsdiagnostiken erhalten können.
Werden Sie Teil der Erfolgsgeschichte von Alacris.
Alacris Theranostics GmbH is a pioneer in the field of Next Generation Sequencing based treatment guidance, clinical trial stratification and biomarker discovery. The company holds a strategic position in the fast growing field of precision medicine by delving deeper into the molecular analysis of tumors, offering a much better chance for optimizing the treatment of cancer patients.
Our unique NGS analysis pipelines, NGSightTM and OncovarTM, integrate whole transcriptome and genome NGS data for tumor analysis, providing the most powerful precision medicine analysis tools currently on the market.
Data-driven personalized therapeutic guidance: CMTA, Comprehensive Molecular Tumor Analysis, provides clinicians with a very comprehensive yet concise and fully annotated output, designed for directly guiding patient-specific therapy. Alacris Theranostics holds an exclusive worldwide license for ModCellTM, a computer modeling system that addresses a critical bottleneck in the development of personalized healthcare solutions. Alacris Theranostics uses its proprietary technology to match the best available drugs to each tumor. ModCellTM can also be used for virtual clinical trials, patient stratification and biomarker identification and provides unique solutions for optimizing drug development and companion diagnostics.
The company currently markets its technologies to a range of customers from private individuals, academic researchers and hospitals to biotechnology and pharmaceutical companies.
Since it was founded in 2008, Alacris Theranostics has attracted strategic investment from Qiagen and is the recipient of numerous competitively peer-reviewed, international and national research grants, including those from the EU Horizon 2020 Programme, the EU Seventh Framework Programme (FP7), the Innovative Medicines Initiative (IMI) and the European Fund for Regional Investment. Current sources of grant funding also include the German Federal Ministry of Education and Research (BMBF) and the Investitionsbank Berlin (IBB), through its GRW (Gemeinschaftsaufgabe “Verbesserung der regionalen Wirtschaftsstruktur”) initiative.
To discuss investment opportunities, please contact us.